Inicio
Entrar
Ayuda
Buscar en este sitio:
Ensayos Registrados
Por tipo de intervención
Por estado de reclutamiento
Por promotor
Por fecha de registro
Búsqueda avanzada de ensayos
Proceso de Registro
Para registrar un ensayo
Formulario del Promotor
Formulario de ensayos del RPCEC
Para actualizar un ensayo registrado
Para reportar los resultados de un ensayo registrado
Inicio
|
Dietzia safety study
View current
Revisiones
List all revisions
Ver
Compare to current
12 Enero 2024 - 6:02pm
por HHA
12 Enero 2024 - 6:07pm
por HHA
Cambios a
Recruitment status
-
Pending
+
Complete
Cambios a
Record Verification Date
-
2023
/
04
/
17
+
2024
/
01
/
12
Cambios a
Next update date
-
2024
/
04
/
17
+
2025
/
01
/
12
Cambios a
Scientific title
-
Safety evaluation of Dietzia
psychralcaliphila
C79793-74 for its use as a probiotic in humans
+
Safety evaluation of Dietzia
natronolimnaea
C79793-74 for its use as a probiotic in humans
Cambios a
Results file
+
sites/default/files/GENERAL INFORMATION OF THE CLINICAL TRIAL.pdf
Revisión de 12 Enero 2024 - 6:07pm
Dietzia safety study
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Scientific title:
Safety evaluation of Dietzia natronolimnaea C79793-74 for its use as a probiotic in humans
Secondary indentifying numbers:
Not applicable
Issuing authority of the secondary identifying numbers:
Not aplicable
Primary sponsor:
Hermanos Ameijeiras Clinical Surgical Hospital
Secondary sponsor:
Not aplicable
Source(s) of monetary or material support:
Biocollective Company, Denver Colorado USA
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Only approved by Ethics Committees
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Gissel
Last name:
Garcia Menendez
Medical Specialty :
PhD in Sciences, Graduate in Biochemistry, Master in Virology
Affiliation:
Hermanos Ameijeiras Clinical Surgical Hospital
Postal address:
San Lazaro 701 corner Belascoain. Havana Center
City:
Havana
País:
Cuba
Zip Code:
10300
Telephone:
+53-78761632
+53-52706385
Email address:
gisselgarcia@infomed.sld.cu
gisselgarcia2805@gmail.com
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Not Applicable
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Complete
Date of first enrollment:
24/04/2023
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
healthy volunteers
Health condition(s) code:
Healthy Volunteers
Intervention(s):
Group I (Experimental) One capsule of Dietzia ssp. C79793–74 (2.5 x109 bacteria /capsule) mixed with the following excipients: dicalcium phosphate, magnesium stearate and colloidal silica). Oral administration, fasting (40 minutes before breakfast) daily for 2 months. Group II (Control) Placebo; same appearance and application scheme as the product
Intervention code:
Probiotics
Dietary Supplements
Placebos
Intervention keyword:
Dietzia ssp.
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Adverse effect (Name of the adverse effect, Does not appear to be an adverse effect, Possible adverse effect, Similar to an adverse effect). Measurement time: After 60 days. Intensity of the adverse effect (Mild, Moderate, Severe). Measurement time: After 60 days.
Key secondary outcomes:
Hematological variables, clinical chemistry, hemodynamic parameters and calculation of muscle mass. Measurement time: All will be measured at the beginning of the study (day 0) and at the end of the study (day 60). Clinical Chemistry: (-Liver enzymes (UKAT/L), -Creatinine (umolL/L), -Urea (mmol/L)) Hematological Parameters: (Blood glucose (mmol/L), Leukocytes (x 109/L), Erythrocytes (x 1012/L), Hemoglobin (g/dL), Ematocrit (%), MCV (fL), MCHC (g/dL) ), RDW (%), platelets (x 109/L), MPV (fL), Neutrophils (%), Lymphocytes (%), Monocytes (%), Eosinophils (%), Basophils (%), Neutrophils (x 109/ L), Lymphocytes (x 109/L), Monocytes (x 109/L), Eosinpophils (x 109/L), Basophils (x 109/L). Hemodynamic Parameters: Systolic blood pressure (mmHg), Diastolic blood pressure (mmHg), Heart rate (bpm). Calculation of muscle mass: For Men: MM=(0.32810*Weight)+(0.33929*height)-29.5336 For Women: MM=(0.29569*weight)+(0.41813*height)-43.2933
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
19 years
Maximum age:
80 years
Inclusion criteria:
1.- Healthy individuals, over 18 years of age and will have no distinction of sex or skin color. 2.- They give their consent to participate in the study. 3.- Individuals with a family history of inflammatory bowel disease. 4.- Individuals who have hematological, clinical chemistry and hemodynamic parameters in normal ranges
Exclusion criteria:
Individuals suffering from any comorbidity. and who show alterations in their hematological, clinical or hemodynamic parameters
Type of population:
Adults
Type of participant:
Healthy volunteers
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Other
Other purpose:
This is a study that will evaluate the probiotic strain Dietzia ssp. C79793–74 in healthy individuals, which has anti-inflammatory properties, so its use will have an impact on intestinal health as well as on improving the immunity of individuals.
Allocation:
Randomized controlled trial
Masking:
Double Blind
Control group:
Placebo
Study design:
Parallel
Phase:
1
Target sample size:
50
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Gissel
Last Name:
Garcia Menendez
Specialty:
PhD in Sciences, Graduate in Biochemistry, Master in Virology
Affiliation:
Hermanos Ameijeiras Clinical Surgical Hospital
Postal Address:
San Lazaro 701 corner Belascoain. Havana Center
City:
Havana
País:
Cuba
Zip Code:
10300
Telephone:
+53-78761632
Email :
gisselgarcia@infomed.sld.cu
gisselgarcia2805@gmail.com
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Gissel
Last Name:
García Menéndez
Specialty:
PhD in Sciences, Graduate in Biochemistry, Master in Virology
Affiliation:
Hermanos Ameijeiras Clinical Surgical Hospital
Postal Address:
San Lazaro 701 corner Belascoain. Havana Center
City:
Havana
País:
Cuba
Zip Code:
10300
Telephone:
+53-78761632
Email :
gisselgarcia@infomed.sld.cu
gisselgarcia2805@gmail.com
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
Hermanos Ameijieras Clinical Surgery Hospital
Status of evaluation:
Approved
Status of evaluation date of Ethic Committee:
15/02/2023
Postal address of Ethic Committee :
San Lazaro 701 corner Belascoain, Havana, ZC 10400, Cuba
Telephone:
+53-78761000
Correo electrónico:
hha@infomed.sld.cu
About study completion
Section to complete the data related to the study completion.
Study completion date:
24/07/2023
Date of available results:
18/12/2023
Date of first publication:
05/02/2024
Results Study
Section to complete the data related to the summarized results.
Results file:
GENERAL INFORMATION OF THE CLINICAL TRIAL.pdf
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000421
Date of Registration in Primary Registry:
17/04/2023
Record Verification Date:
2024/01/12
Next update date:
2025/01/12
Link to the spanish version:
Click here
Acerca del RPCEC
Estructura y Gobernanza
Política
Publicaciones
Reconocimientos
Comunicaciones
Noticias
Recursos útiles
Fundamentos del registro
Bibliografías en ensayos clínicos
Regulaciones cubanas
Otros registros
Plataforma Internacional de Registros de Ensayos Clínicos